Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 345

Sort by

Sort Order Select

Journal Articles

Importance of predicting CML therapy failure

Giuseppe Saglio

Blood (2024) 144 (18): 1852–1853.

https://doi.org/10.1182/blood.2024026119

Published: 2024

Journal Articles

Discovery of Mutated MUC3A Gene As a Novel Transcription Factor Exclusively Associated with Accelerated Phase Chronic Myeloid Leukemia: Hunt for Common Biomarker of Fatal CML Progression

Sameen Shahid, Muhammad Sabar, Abid Jamil, Muhammad Abbas Khokar, Muhammad Absar, Mudassar Iqbal, Masood A. Shammas, Giuseppe Saglio, Sulman Basit, Sibtain Afzal, Khushnooda Ramzan, Aamer Aleem, Amer Mahmood, Nawaf Alanzazi, Muhammad Javed Asif, Mahmood Rasool, Ahmad Khalid, Zafar Iqbal

Blood (2023) 142 (Supplement 1): 7429.

https://doi.org/10.1182/blood-2023-185547

Published: 2023

Journal Articles

Full Treatment-Free Remission Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Following One Year of Nilotinib De-Escalation: 96-Week Update of Dante Study

Alessandra Iurlo, Massimo Breccia, Fabio Stagno, Elisabetta Abruzzese, Fabrizio Pane, Immacolata Attolico, Paolo Sportoletti, Marco Cerrano, Sara Galimberti, Barbara Scappini, Maurizio Miglino, Sergio Siragusa, Isabella Capodanno, Diletta Valsecchi, Aurelio Pio Nardozza, Alessandra Misto, Paola Coco, Giuseppe Saglio, Gianantonio Rosti

Blood (2023) 142 (Supplement 1): 4534.

https://doi.org/10.1182/blood-2023-180131

Published: 2023

Journal Articles

Centralized MRD Assessment at Early Timepoints in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk AML

Blood (2023) 142 (Supplement 1): 1567.

https://doi.org/10.1182/blood-2023-189777

Published: 2023

Journal Articles

Efficacy of Frontline Treatment with Initial Low-Dose Tyrosine-Kinase Inhibitors in Elderly Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Blood (2023) 142 (Supplement 1): 3176.

https://doi.org/10.1182/blood-2023-186406

Published: 2023

Journal Articles

International, Prospective Study Comparing Nilotinib Versus Imatinib with Early Switch to Nilotinib to Obtain Sustained Treatment-Free Remission in Patients with Chronic Myeloid Leukemia (SUSTRENIM trial): Analysis of the Eligibility to Treatment Discontinuation

Blood (2023) 142 (Supplement 1): 3169.

https://doi.org/10.1182/blood-2023-182220

Published: 2023

Journal Articles

The Use of 2 nd Generation TKIs As First Line Therapy Does Not Prevent CML Related Deaths: Results of an Italian CML Campus Prospective Study in 1277 Patients Treated First Line with Imatinib or 2 nd Generation TKIs

Blood (2023) 142 (Supplement 1): 3168.

https://doi.org/10.1182/blood-2023-182981

Published: 2023

Journal Articles

Asciminib (ASC) Add-on to Imatinib (IMA) Demonstrates Sustained High Rates of Ongoing Therapy and Deep Molecular Responses (DMRs) with Prolonged Follow-up in the ASC4MORE Study

Timothy P Hughes, Giuseppe Saglio, Jan Geissler, Dong-Wook Kim, Elza Lomaia, Jiri Mayer, Anna Turkina, Shruti Kapoor, Ana Paula Torres Cardoso, Jomy Jose, Monali Sura, Jorge Cortes

Blood (2023) 142 (Supplement 1): 866.

https://doi.org/10.1182/blood-2023-182100

Published: 2023

Journal Articles

Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase Showing Clinical Resistance to Frontline Treatment with Second Generation Tyrosine Kinase Inhibitors. an Italian Prospective Study from the CML Campus

Blood (2023) 142 (Supplement 1): 6363.

https://doi.org/10.1182/blood-2023-188523

Published: 2023

Journal Articles

Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Younger Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Blood (2023) 142 (Supplement 1): 1811.

https://doi.org/10.1182/blood-2023-188934

Published: 2023

Journal Articles

Efficacy and Safety Results from ASC4MORE, a Randomized Study of Asciminib (ASC) Add-on to Imatinib (IMA), Continued IMA, or Switch to Nilotinib (NIL) in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Not Achieving Deep Molecular Responses (DMRs) with ≥1 Year of IMA

Jorge E. Cortes, Timothy Hughes, Jan Geissler, Dong-Wook Kim, Elza Lomaia, Jiri Mayer, Anna G. Turkina, Sarah Hurwicz Kogut, Ana Paula Torres Cardoso, Monali Sura, Giuseppe Saglio

Blood (2022) 140 (Supplement 1): 195–197.

https://doi.org/10.1182/blood-2022-167177

Published: 2022

Journal Articles

Patient Specific Droplet Digital PCR Targeting FLT3-ITD Allows to Detect Small Clones in Acute Leukemias at Diagnosis and during Follow-up

Daniela Cilloni, Johanna Umurungi, Valentina Bonuomo, Federico Itri, Cristina Rotolo, Silvia Marini, Monia Lunghi, Andrea Castelli, Carmen Fava, Giuseppe Saglio, Alessandro Cignetti, Jessica Petiti

Blood (2022) 140 (Supplement 1): 11827–11828.

https://doi.org/10.1182/blood-2022-167017

Published: 2022

Journal Articles

Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN

Jorge E. Cortes, Qian Jiang, Jianxiang Wang, Jianyu Weng, Huanling Zhu, Xiaoli Liu, Andreas Hochhaus, Dong-Wook Kim, Jerald Radich, Michael R. Savona, Patricia Martin-Regueira, Oumar Sy, Giuseppe Saglio

Blood (2022) 140 (Supplement 1): 9647–9649.

https://doi.org/10.1182/blood-2022-164444

Published: 2022

Journal Articles

Treatment-Free Remission Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Following One Year of Nilotinib De-Escalation: 96-Week Update of Dante Study

Fabio Stagno, Elisabetta Abruzzese, Alessandra Iurlo, Fabrizio Pane, Imma Attolico, Paolo Sportoletti, Patrizia Pregno, Sara Galimberti, Barbara Scappini, Maurizio Miglino, Sergio Siragusa, Isabella Capodanno, Diletta Valsecchi, Aurelio Pio Nardozza, Paola Coco, Gianantonio Rosti, Giuseppe Saglio, Massimo Breccia

Blood (2022) 140 (Supplement 1): 9614–9616.

https://doi.org/10.1182/blood-2022-157700

Published: 2022

Journal Articles

A Phase II, Single-Arm Study of De-Escalation and Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line Therapy Followed By a Second Attempt after Nilotinib and Asciminib Combination: Dante Study

Gianantonio Rosti, Giuseppe Saglio, Fabio Stagno, Diletta Valsecchi, Aurelio Pio Nardozza, Paola Coco, Massimo Breccia, Alessandra Iurlo

Blood (2022) 140 (Supplement 1): 9643–9644.

https://doi.org/10.1182/blood-2022-157002

Published: 2022

Journal Articles

A Radiation-Free Approach Based on the Whole-Body-MRI Has Shown a High Level of Accuracy in the Follow up of Lymphoma Patients. a Single Center Retrospective Study

Antonio Frolli, Silvia Varvello, Annalisa Balbo Mussetto, Daniela Gottardi, Martina Bullo, Silvia Marini, Giuseppe Saglio, Stefano Cirillo, Daniela Cilloni, Guido Eugenio Parvis

Blood (2022) 140 (Supplement 1): 9317.

https://doi.org/10.1182/blood-2022-168519

Published: 2022

Journal Articles

Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Blood (2022) 140 (Supplement 1): 1705–1707.

https://doi.org/10.1182/blood-2022-157393

Published: 2022

Journal Articles

Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A "Campus CML" Study

Blood (2022) 140 (Supplement 1): 3920–3922.

https://doi.org/10.1182/blood-2022-164790

Published: 2022

Journal Articles

Permanent Discontinuation of Tyrosine Kinase Inhibitor Frontline Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Patients during the First 36 Months of Treatment: A "Campus CML" Study

Blood (2022) 140 (Supplement 1): 3906–3907.

https://doi.org/10.1182/blood-2022-170415

Published: 2022

Journal Articles

Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Immunolipsome Loaded Venetoclax

Mohammad Houshmand, PhD, Paola Circosta, PhD, Francesca Garello, PhD, Valentina Gaidano, MD, Alessandro Cignetti, MD PhD, Rachele Stefania, Silvio Aime, PhD, Giuseppe Saglio, MD PhD

Blood (2020) 136 (Supplement 1): 39.

https://doi.org/10.1182/blood-2020-142540

Published: 2020

NARROW

Importance of predicting CML therapy failure

Discovery of Mutated MUC3A Gene As a Novel Transcription Factor Exclusively Associated with Accelerated Phase Chronic Myeloid Leukemia: Hunt for Common Biomarker of Fatal CML Progression

Full Treatment-Free Remission Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Following One Year of Nilotinib De-Escalation: 96-Week Update of Dante Study

Centralized MRD Assessment at Early Timepoints in Gimema AML1718 Trial, a Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk AML

Efficacy of Frontline Treatment with Initial Low-Dose Tyrosine-Kinase Inhibitors in Elderly Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

International, Prospective Study Comparing Nilotinib Versus Imatinib with Early Switch to Nilotinib to Obtain Sustained Treatment-Free Remission in Patients with Chronic Myeloid Leukemia (SUSTRENIM trial): Analysis of the Eligibility to Treatment Discontinuation

The Use of 2 nd Generation TKIs As First Line Therapy Does Not Prevent CML Related Deaths: Results of an Italian CML Campus Prospective Study in 1277 Patients Treated First Line with Imatinib or 2 nd Generation TKIs

Asciminib (ASC) Add-on to Imatinib (IMA) Demonstrates Sustained High Rates of Ongoing Therapy and Deep Molecular Responses (DMRs) with Prolonged Follow-up in the ASC4MORE Study

Outcome of Patients with Chronic Myeloid Leukemia in Chronic Phase Showing Clinical Resistance to Frontline Treatment with Second Generation Tyrosine Kinase Inhibitors. an Italian Prospective Study from the CML Campus

Baseline Features, Treatment Choice and Early Frontline TKI Permanent Discontinuation in Younger Patients with Chronic Myeloid Leukemia: A “Campus CML” Study

Efficacy and Safety Results from ASC4MORE, a Randomized Study of Asciminib (ASC) Add-on to Imatinib (IMA), Continued IMA, or Switch to Nilotinib (NIL) in Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Not Achieving Deep Molecular Responses (DMRs) with ≥1 Year of IMA

Patient Specific Droplet Digital PCR Targeting FLT3-ITD Allows to Detect Small Clones in Acute Leukemias at Diagnosis and during Follow-up

Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN

Treatment-Free Remission Outcome in Patients with Chronic Myeloid Leukemia in Chronic Phase Following One Year of Nilotinib De-Escalation: 96-Week Update of Dante Study

A Phase II, Single-Arm Study of De-Escalation and Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line Therapy Followed By a Second Attempt after Nilotinib and Asciminib Combination: Dante Study

A Radiation-Free Approach Based on the Whole-Body-MRI Has Shown a High Level of Accuracy in the Follow up of Lymphoma Patients. a Single Center Retrospective Study

Gimema AML1718 Part 1: Planned Interim Analysis of a Safety Run-in and Phase 2 Open-Label Study of Venetoclax, Fludarabine, Idarubicin and Cytarabine (V-FLAI) in the Induction Therapy of Non Low-Risk Acute Myeloid Leukemia

Choice of Tyrosine Kinase Inhibitor and Early Events during the First Year of Therapy in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) Patients with Concomitant Diabetes: A "Campus CML" Study

Permanent Discontinuation of Tyrosine Kinase Inhibitor Frontline Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Patients during the First 36 Months of Treatment: A "Campus CML" Study

Targeting Chronic Myeloid Leukemia Stem/Progenitor Cells Using Immunolipsome Loaded Venetoclax

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only